About Us

Our Vision

Antibiotic resistance is a serious public health crisis. As resistance to antibiotics grows, it becomes increasingly difficult to effectively manage a wide range of infections, which often results in poor outcomes for patients and escalating healthcare costs. Our vision is to improve patients’ health and outcomes by creating innovative, life-saving medicines to treat serious infectious diseases caused by drug-resistant Gram-negative bacteria.

Our Values

At Entasis, we are driven by our passion for innovation to overcome challenging scientific problems and commitment to deliver new therapies to treat life-threatening infections.  Our culture is built upon creativity, diversity, mutual respect, effective communication and interdisciplinary teamwork.  We measure our success by the positive impact our medicines have on patient health.

Our Company

Entasis Therapeutics was established in 2015 with start-up funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. In March 2016, we raised an additional $50 million in a Series B financing from a strong syndicate of investors, including Clarus, Frazier Healthcare Partners, Novo A/S and Eventide Funds, to advance our pipeline of breakthrough anti-infective products.

We are a team of scientists and experts with the culture and energy of a small biotech, combined with the expertise and portfolio of a global pharmaceutical company. Our leaders and scientists have deep expertise, and a track record of discovery, development and commercialization of innovative anti-infectives from biotech, academia and big pharma.

With our expertise and a unique pathogen-targeted approach, we have developed a robust clinical and pre-clinical pipeline of first- and best-in-class medicines. This includes small-molecule programs to treat serious multidrug-resistant Gram-negative infections, including Acinetobacter baumanniiPseudomonas aeruginosa and Enterobacteriaceae, and a single dose oral therapy for susceptible and drug-resistant Neisseria gonorrhoeae.

“Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multidrug-resistant bacterial infections.”

— Ruben Tommasi, Chief Scientific Officer